NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
Canada - TSX-V:NSCI - CA63000Y1034 - Common Stock
0.185 CAD
0 (0%)
Taking everything into account, NSCI scores 4 out of 10 in our fundamental rating. NSCI was compared to 16 industry peers in the Health Care Equipment & Supplies industry. NSCI has a bad profitability rating. Also its financial health evaluation is rather negative. NSCI may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
NSCI had negative earnings in the past year.
In the past year NSCI had a positive cash flow from operations.
NSCI had negative earnings in each of the past 5 years.
NSCI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NSCI has a better Return On Assets (-33.34%) than 87.50% of its industry peers.
Looking at the Return On Equity, with a value of -99.08%, NSCI belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 28.40%, NSCI is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of NSCI has declined.
The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NSCI has more shares outstanding than it did 1 year ago.
NSCI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NSCI has a worse debt to assets ratio.
2.2 Solvency
NSCI has an Altman-Z score of -0.67. This is a bad value and indicates that NSCI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.67, NSCI is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
The Debt to FCF ratio of NSCI is 352.74, which is on the high side as it means it would take NSCI, 352.74 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 352.74, NSCI belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
A Debt/Equity ratio of 0.72 indicates that NSCI is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.72, NSCI is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Altman-Z | -0.67 |
ROIC/WACCN/A
WACC5.79%
2.3 Liquidity
NSCI has a Current Ratio of 0.87. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of NSCI (0.87) is better than 62.50% of its industry peers.
NSCI has a Quick Ratio of 0.87. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NSCI (0.61) is better than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
NSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.12%, which is quite good.
The Revenue has grown by 9.01% in the past year. This is quite good.
The Revenue has been growing by 40.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
3.2 Future
NSCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.08% yearly.
The Revenue is expected to grow by 5.48% on average over the next years.
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y36.08%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.48%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 4.58, the valuation of NSCI can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NSCI indicates a rather cheap valuation: NSCI is cheaper than 100.00% of the companies listed in the same industry.
NSCI is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.58 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NSCI is valued cheaply inside the industry as 93.75% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NSCI indicates a rather cheap valuation: NSCI is cheaper than 93.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 424.83 | ||
| EV/EBITDA | 51.28 |
4.3 Compensation for Growth
NSCI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NSCI's earnings are expected to grow with 45.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
No dividends for NSCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (10/22/2025, 7:00:00 PM)
0.185
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.54%
Inst Owner ChangeN/A
Ins Owners3.96%
Ins Owner ChangeN/A
Market Cap21.24M
Revenue(TTM)43.03M
Net Income(TTM)-12525000
Analysts80
Price Target0.84 (354.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)0
Avg EPS beat(4)-98.02%
Min EPS beat(4)-98.02%
Max EPS beat(4)-98.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.55%
Min Revenue beat(2)-7.95%
Max Revenue beat(2)-7.14%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-7.95%
Max Revenue beat(4)16.28%
Revenue beat(8)5
Avg Revenue beat(8)11.79%
Revenue beat(12)7
Avg Revenue beat(12)5.02%
Revenue beat(16)8
Avg Revenue beat(16)1.86%
PT rev (1m)0%
PT rev (3m)-13.16%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.58 | ||
| P/S | 0.49 | ||
| P/FCF | 424.83 | ||
| P/OCF | 11.45 | ||
| P/B | 1.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 51.28 |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.04
Fwd EY21.84%
FCF(TTM)0
FCFY0.24%
OCF(TTM)0.02
OCFY8.73%
SpS0.37
BVpS0.11
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.34% | ||
| ROE | -99.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.4% | ||
| FCFM | 0.12% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score5
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 352.74 | ||
| Debt/EBITDA | 12.75 | ||
| Cap/Depr | 42.03% | ||
| Cap/Sales | 4.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 261.64% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | -0.67 |
F-Score5
WACC5.79%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.65%
EPS Next Y81.82%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y36.08%
Revenue 1Y (TTM)9.01%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-16.54%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.48%
EBIT growth 1Y52.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.7%
EBIT Next 3Y72.2%
EBIT Next 5Y55.02%
FCF growth 1Y100.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y113.25%
OCF growth 3YN/A
OCF growth 5Y33.1%